Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

ESSA Pharma Inc (EPIX)

NASDAQ
Currency in USD
Disclaimer
6.08
-0.04(-0.65%)
Closed

EPIX Comments

ESSA Pharma recently presented some impressive data at the European Society of Medical Oncology 2023 Congress. They've been working on this game-changing drug called masofaniten (previously known as EPI-7386), and the results are turning heads. Masofaniten is a novel androgen receptor inhibitor, a new kind of treatment for prostate cancer that works differently from anything else out there. Prostate cancer is a major issue worldwide, reaching millions of people, and ESSA's approach is innovative. Their drug specifically targets the N-terminal domain of the androgen receptor, a pathway crucial in prostate cancer growth. What's more, this pathway hasn't been targeted by other therapies yet, which positions masofaniten as a potential first-in-class drug. The data from their Phase 1/2 trials is what's really stirring up excitement. In these trials, masofaniten, combined with another drug called enzalutamide, showed deep and durable reductions in prostate-specific antigen (PSA) levels in patients. These reductions are a big indicator of the drug’s effectiveness against metastatic castration-resistant prostate cancer. And guess what? Most of the patients showed significant improvements. The U.S. Food and Drug Administration has granted Fast Track designation to masofaniten for this specific cancer treatment. Plus, ESSA retains all rights to masofaniten globally, which is huge for its valuation and potential profits.
https://www.urologytimes.com/view/masofaniten-plus-enzalutamide-shows-promise-in-mcrpc
ESSA Pharma recently presented some impressive data at the European Society of Medical Oncology 2023 Congress. They've been working on this game-changing drug called masofaniten (previously known as EPI-7386), and the results are turning heads. Masofaniten is a novel androgen receptor inhibitor, a new kind of treatment for prostate cancer that works differently from anything else out there. Prostate cancer is a major issue worldwide, reaching millions of people, and ESSA's approach is innovative. Their drug specifically targets the N-terminal domain of the androgen receptor, a pathway crucial in prostate cancer growth. What's more, this pathway hasn't been targeted by other therapies yet, which positions masofaniten as a potential first-in-class drug. The data from their Phase 1/2 trials is what's really stirring up excitement. In these trials, masofaniten, combined with another drug called enzalutamide, showed deep and durable reductions in prostate-specific antigen (PSA) levels in patients. These reductions are a big indicator of the drug’s effectiveness against metastatic castration-resistant prostate cancer. And guess what? Most of the patients showed significant improvements. The U.S. Food and Drug Administration has granted Fast Track designation to masofaniten for this specific cancer treatment. Plus, ESSA retains all rights to masofaniten globally, which is huge for its valuation and potential profits. If masofaniten continues to show promise in its ongoing Phase 2 trials, we could be looking at a significant breakthrough in prostate cancer treatment. And as investors know, breakthroughs like this don't just save lives; they also create substantial financial opportunities.
EPIX @$50 in summer 2020 ?
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.